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ABSTRACT 
The pharmaceutical Carvedilol acts as a non-selective beta (ßi/ßi) 
and selective alpha (cq) adrenoceptor antagonist, cardioprotector, 
antioxidant, oxidative phosphorylation uncoupler, and amyloid-beta (Aj6) 
anti-fibrillar agent. Given its diverse pharmacodynamic profile, the 
resolution of carvedilol's highly populated conformations are a necessary 
prerequisite to divulging the basis of its molecular interactions. However, 
given carvedilol's sizeable conformational potential energy hypersurface 
(PEHS) - 11 torsional angles and 177 147 (311) conformational 
possibilities - this task requires a creative approach as traditional brute 
force multi-dimensional conformational analysis (MDCA) is impractical. 
Using Carvedilol as a case study, a novel theoretical method entitled 
rational molecular fragmentation was developed for the structural and 
conformational study of complex drug molecules that minimizes 
computational and experimental resources. Rational molecular 
fragmentation was based on dividing Carvedilol into simpler 
pharmacophore fragments (carbazole Fragment A, secondary amine 
Fragment B, and di-substituted benzene Fragment C) with manageable 
PEHSs but still relevant to the electronic structure of whole Carvedilol. 
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Each fragment was analyzed via gas phase Hartree-Fock [RHF/3-21G and 
RHF/6-31G(d)] and B3LYP/6-31G(d) density functional theory (DFT 
with the Becke 3LYP hybrid exchange-correlation functional) MDCA to 
disclose and assess dominant structures, structural motifs, conformational 
intricacies, stereochemical relationships (i.e., point chirality and axis 
chirality), multiple proton conformational basicity (particular to primary 
and secondary amines) parameters, and intramolecular attractive forces 
(IMAF) relevant to each fragment and to carvedilol. The dominant (low 
energy) fragment conformations, once optimized and evaluated, were used 
to hypothesize and predict a total of 240 carvedilol conformers which 
were initially optimized at the RHF/3-21G level of theory revealing 121 
converged structures. An authentic set of nine converged low energy 
conformations were discovered and examined with DFT calculations in 
gas and solvent (DMSO and water). Independent NMR spectroscopy (in 
DMSO) was performed for further structural analysis and to verify the 
accuracy of this fragmentation method. Gas phase results show that seven 
of the nine conformers possess a novel tetra-centric spiro-type 
conformation composed of intramolecular six- and eight-menrbered rings. 
This structural motif is dictated by the positive nitrogen centr e and by the 
inflexibility of the carbazole aromatic ring. DMSO and water DFT 
optimizations and NMR spectroscopy closely mirror each other indicating 
that carvedilol has a subtle energetic and structural solvent effect and a 
significant barrier to re-arrangement from gas phase to solvent exists. 
Given the harmony achieved between theoretical and experimental results, 
this study suggests the most populated states of carvedilol expected to 
dominate physical and biological samples and gives credence to the ability 
of methodically analyzing complex molecular systems by means of 
theoretical structure-activity fragmentation. Together, this will critically 
aid the molecular understating of carvedilol's pharmacodynamic 
mechanisms and structural underpinnings. 
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1. INTRODUCTION 
1.1 Biological & Pharmacodynamic Review of Carvedilol 
The cardiovascular pharmaceutical Carvedilol, l-[carbazolyl-(4)-
oxy]-3-[(2-methoxyphenoxyethyl)amino]-2-propanol (C24H26N2O4), is a 
hydrophobic aryloxypropanolamine multiple-action neurohormonal 
antagonist. Carvedilol is used in the treatment of mild-to-moderate 
essential hypertension, stable angina pectoris, ischemic heart disease 
(IHD), and mild-to-moderate chronic congestive heart failure (CHF). 
(Note that * denotes stereocentre in figure below.) 
ß|/ß,-BLOCKER 
Carvedilol provides hemodynamic benefits such as peripheral 
vasodilation and reduction in cardiac work from balanced non-selective ¡3-
adrenoceptor blockage (/3|//32) and selective «i-receptor blockage. With 
regards to cardioprotection, carvedilol exerts anti-proliferative/anti-
atherogenic, anti-hypertrophic, anti-ischemic, and anti-arrhythmic actions 
by means of antioxidant effects, improvement of glucose and lipid 
metabolism, modulation of neurohumoral factors, and beneficial cardiac 
electrophysiological properties (K+ and Ca2+ ion channels). 
Carvedilol protects mitochondria from oxidative stress by 
uncoupling oxidative phosphorylation via a weak protonophoretic (proton 
transfer) mechanism involving the amino group (pKa = 7.9) of its side-
chain. This phenomenon known as "mild uncoupling" occurs when a 
small decrease in mitochondrial electric potential induces a significant 
reduction in the ROS produced by the mitochondrial respiratory chain. It 
has been shown that carvedilol and its active hydroxylated analogues act 
as novel anti-fibrillar agents able to inhibit amyloid-beta (A/3) fibril 
formation and may have uses in the prevention or slowing down of 
Alzheimer's disease (AD) pathology. It is currently not known if 
carvedilol binds to A/3 monomers, dimers, or other oligomers or what type 
of interaction occurs between carvedilol and the A/3 peptide(s). 
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Given the multi-faceted nature of carvedilol, it is necessary to 
reveal its complete molecular identity and conformational profile as a 
means to fully divulge the structural properties of its adrenoceptor binding 
conformation and further clarify its function in hemodynamic and 
cardioprotective mechanisms. Likewise, to expound carvedilol's role in 
antioxidant pathways, the uncoupling of oxidative phosphorylation in 
mitochondria, and with A/3 peptide(s) in AD, its conformational identity is 
requisite as conformation is a fundamental part of all of these processes. 
However, given carvedilol's 11 associated torsional angles and 177 147 
(311) conformational possibilities [total is arrived at by multi dimensional 
conformational analysis (MDCA) where each torsional angle can assume 
gauche plus, anti, or gauche minus orientations], this task is exceptionally 
extensive. To remedy this quandary, we have developed a method entitled 
rational molecular fragmentation to study large complex molecular 
systems in great detail. The cardiovascular pharmaceutical carvedilol will 
be used as a case study illustrating how this method is developed, drawn 
on, and delegated to reveal the structural and conformational intricacies of 
a particular molecular system. Given the lack of novel methods available, 
it is hoped that this model can be extrapolated for further investigations. 
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1.2 Stereogenic Units of Carvedilol 
Carvedilol exists as a racemic mixture of both enantiomers /?(+) 
and S(-). However, carvedilol's enantiomers show marked stereoselective 
properties in that both stereoisomers have equal ai-adrenoceptor blocking 
activity but only the £(-) enantiomer possesses the nonselective p-
adrenergic antagonist activity. This represents an unusual situation in 
which enantiomers of an optically active drug differ not only 
quantitatively in terms of potency but also qualitatively in that they 
possess distinct pharmacologic profiles. 
Optical isomerism provides evidence about the chiral disposition 
of electron density in space around the nuclei. Essentially, the chirality of 
the electron density exists irrespective of whether it is associated with a 
carbon carrying four different substituents (point chirality) or if it is I 
associated with the asymmetric electron distribution caused by a 
conformational twist (axis chirality). Since chirality is central to the 
structure of any molecular system, the stereogenic units of carvedilol are 
investigated to highlight how point and axis chirality can be used to 
predict electronic structure and energetics of corresponding chiral minima. 
2. AIM OF STUDY 
This dissertation is carried out with a fourfold aim: (1) devise a 
novel structure-activity fragmentation method with substantial predictive 
power and minimal computational cost to assess and analyze the 
conformations of selected carvedilol molecular fragments and to predict 
the conformations of carvedilol; (2) evaluate the stereochemical 
relationships, emphasizing point chirality and axis chirality, of carvedilol 
since its pharmacologic profiles are unique in their stereochemical 
reliance; (3) examine the dependence of basicity (proton affinity) on 
conformation as is relevant to carvedilol's role as a physiological base in 
mitochondria uncoupling; (4) discover, determine, and depict the 
electronic structure of carvedilol's most populated (lowest energy) 
conformations expected to dominate physical and biological samples. 
The comprehensive solution of carvedilol's conformational 
character and related structural parameters will greatly aid the molecular 
discernment of its pharmacodynamic mechanisms. Furthermore, 
satisfactory success of the application of this developed rational molecular 
fragmentation method for the structural analysis of carvedilol may 
indicate its viability for the study of other complex molecular systems 
with regards to broad prediction and analysis of electronic structure, 
stereochemical, and conformational parameters. 
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3. METHODS 
Gas and solvent (Onsager solvent reaction field method) phase 
theoretical ab initio [restricted Hartree-Fock, RHF/3-21G and RHF/6-
3 lG(d)] and density functional theory [DFT, B3LYP/6-31G(d)] quantum 
chemical molecular orbital (MO) computations were employed for the 
development of the rational molecular fragmentation method and for all 
carvedilol and fragment structural, stereochemical, and proton affinity 
investigations. Additionally, MO computations were used to gauge the 
accuracy and ability of the devised method to predict the preferred 
conformations of carvedilol. All computations were carried out using 
GAUSSIAN98 software program. NMR spectroscopy was utilized for the 
structural analysis of carvedilol, to compare experimentally- and 
theoretically-determined structures, and to further assess the success of the 
molecular fragmentation approach. 
THESES 
Thesis #1 
Using the pharmacophore, I have divided carvedilol into three molecular 
fragments as the basis of the model of rational molecular fragmentation: 
R- and 5-4-(2-hydroxypropoxy)carbazol (Fragment A), 2(R and 5)-l-
(ethylamonium)propane-2-ol (Fragment B), and aminoethoxy-2-methoxy-
benzene (Fragment C). 
Xi = C23-01-C2-C3 X3 = C29-C24-C23-01 
x2 = C24-C23-01-C2 xio = H30-025-C24-C23 
Fragment A 
X7 = 05-C4-C3-N2 x? - C7-C6-05-C4 
Xs - C6-0S-C4-C3 Xll - C13-0I2-CI 1-Cft 
Fragment C 
Xi - N5-C4-C3-C2 
X5 - C6-N5-C4-C3 
X6»C7-C6-N5-C4 
XIO- H12-011-C3-C2 
Fragment B 
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Thesis #15 
I have performed gas phase MDCA on and ^-Fragment A at the 
RHF/3-21G, RHF/6-31 G(d), and B3LYP/6-31G(d) levels of theory and 
discovered 19 DFT optimized minima out of a possible 81 conformational 
states (23%). I have presented the dominant intramolecular attractive 
forces (IMAF) of ^-Fragment A to be H-bonding between Ol and H30 
leading to the formation of an intramolecular five-membered ring which 
confers both electrostatic (via the H-bond) and steric (via the five-
membered ring) relaxation to the side-chain of Fragment A. (DFT relative 
energies of the structures below is indicated in parentheses in Kcal'mol'1.) 
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Thesis #3 
I have optimized 5-Fragment B with MDCA at the RHF/3-21G level of 
theory to uncover a total of 18 converged minima out of a possible 81 
(22.2%). I found the dominant structural characteristic to be that all 
minima possess torsional angle Xio in the g+ position and all low energy 
structures possess an H-bond between 011 and the HS/HÄ protons 
resulting in a five-membered ring similar to the global minima aaag+. 
aaag+ 
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Thesis #4 
I have performed MDCA on Fragment C at the RHF/3-21G level of 
theory and have revealed that, instead of the expected 81 conforméis, a 
total of 24 converged minima were found (30% convergence). I have 
discovered that the Fragment C PEHS global minima is conformer 
g+g+g+g- which possess an eight-membered ring formed by a short H-
bond between HI and 012 and a longer H-bond between HI and 05 
forming a five-membered ring. 
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Thesis #5 
8+g+g+g-
I have analyzed and presented the structural and energetic basis of point 
chirality and axis chirality by MDCA of S- and /¿-Fragment A along with 
designed pro-chiral and chiral analogues II-H2, II-Me2, III-[H,Me]-5, III-
[H,Me]-/?, IV-H2, and IV-Me2. All structures were optimized at the 
RHF/3-21G, RHF/6-31G(d), and B3LYP/6-31G(d) levels of theory to 
illustrate the stereochemical relationships of carvedilol and its fragments. 
J f< 
Xi = C23-01-C2-C3 
X2 = C24-C23-01-C2 
X3 = C29-C24-C23-01 
/*" Xlu = H30-025-C24-C23 
E = fIXl.X2.X3,XiuJ 
(2-hydro.\> cihaxy)carbazol 
(analogue I l -Hj ) 
(2-hydro.\y-2-nteihyl-eiho.\y)carbazol ^ y 
(analogue U - M e j ) 
(2R)-1 -nicihoxypropan-2-oI 
(analogue UI- |H.Me]- / i ) > 
X2 = C5-C4-03-C2 
X3 = 06-C5-C4-03 
Xio = H7-06-C5-C4 
E = f(X2. X3. Xio.) 
Thesis #15 
I have determined that the energetic and structural i?-carvedilol parameters 
presented can be promptly extrapolated to S-carvedilol as all enantiomeric 
minima will be paired up according to the equation below. Optimized 
parameters for a converged minima of /Tcarvedilol require the switching 
of point chirality from the R- to S-stereoisomer followed by the switching 
of optimized torsional angle geometries (i.e., axis chirality) from 
clockwise to counterclockwise rotation. 
Er = Es 
Windex of Xi to Xn) = fs(index of-Xi to -Xn) 
Thesis #7 
I have shown that there is a direct dependence of multiple proton basicity 
on conformation for the secondary amine Fragment B and the primary 
amine Fragment C as protons will be biased depending on conformation 
and IMAF adopted. For both fragments, conformers devoid of IMAF 
display lower energies of deprotonation. (The graph below displays the 
basicity character of Fragment B.) 
H-bonded proton 
/ N ^ 
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•• V . . \ \ 
_J \ 
internal H-bonding^ : 
no internal 
H-bonding 
Given the results obtained for Fragment B and C, I have postulated that 
the differences in carvedilol's energies of deprotonation, which have 
previously been attributed to uncharacterized conformation factors, are 
likely related to the dependence of basicity on conformation. This has 
implications in carvedilol's uncoupling of oxidative phosphorylation in 
mitochondria. 
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Thesis #15 
I have utilized converged low energy (defined as possessing a conformer 
relative energy <2.00 Kcal'mol"1) Fragment A, B, and C conformations to 
predict a comprehensive list of 240 non-redundant R-carvedilol 
conformers hypothesized to be low energy states. I have optimized the 
240 predicted structures at the RFIF/3-21G level of theory and discovered 
a total of 121 unique carvedilol conformations spanning a rage of 275 
conformational assignments (121/275 = 44%) and possessing a range in 
relative conformer energy o f - 2 3 Kcal'mol"1. 
Thesis #9 
I have selected a definitive and authentic set of nine Hartree-Fock 
optimized low energy conformers for the carvedilol PEHS by analyzing a 
graphical plot of all converged conformations according to their respective 
relative energy. The nine low energy structures are bound by a conformer 
relative energy of less than four Kcal'mol"1 and are clearly divided from 
the rest of the converged structures. I selected the nine conformations, C-
7?-246 to C-/Z-251, C-R-258, C-R-272, C-R-273, for further gas and 
solvent phase optimization with high level DFT calculations. 
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Thesis #15 
I have optimized the nine low energy carvedilol structures in the gas phase 
at the B3LYP/6-31G(d) level of theory (all nine conformations exhibit a 
gas phase relative energy of less than two Kcabmol"') and determined that 
seven (C-R-246 to C-^-250, C-^-258, and C-R-212) of the nine 
conformations possess a novel "tetra-centric" structural motif. The tetra-
centric conformation consists of the 13-membered aromatic carbazole ring 
(centre 1), an O H-N H-bonded six-membered ring (ring a; centre 2), an 
O " H-N H-bonded eight-membered ring (ring b; centre 3), and the di-
substituted benzene ring (centre 4). 
\ r \ 
Thesis #11 
I have concluded the gas phase global minima of the carvedilol PEHS to 
be conformer C-R-249. 
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Thesis #15 
I have characterized the solvent effect of Carvedilol with DFT DMSO and 
water solvation optimizations and have displayed that Carvedilol has a 
subtle solvent effect with regards to energetics and electronic structure. 
On the whole, DMSO and water produced the same solvent effect and 
most structures preferred the tetra-centric motif seen in the gas phase 
suggesting there are significant conformational transition state energy 
barriers that affect the interconversion rates between the different 
conformational states. (Note that the DMSO and water relative energies 
extensively overlap each other in the figure below.) 
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Carvedilol Structure Code C-R-x 
Thesis #13 
I have theoretically resolved carvedilol's conformational surface along 
with all torsional angle orientations necessary for carvedilol to assume its 
low energy states (summarized in the equation below). 
Xi = g+ia XL = a Xs=g-
X4 = g+ Xs = g+ia & = g+lalg-
X? = g+/g- Xs = g+lalg- X, = g+/g-
Xio = g+ Xn =g+lalg-
Thesis #14 
I have determined from ROESY spectra (in DMSO) that there is rigid 
motion about torsional angles Xi> X2, X3» %», and Xs as determined from the 
fact that protons H39/H40 and H44/H45 are not equivalent, and as a 
result, rotation about these torsional angles is likely hindered by strong 
and persistent intramolecular H-bond networks. Thus, I have concluded 
that the independent NMR ROESY spectra substantiate the DFT 
optimized structures. 
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Thesis #15 
I have evaluated that, according to conformation distribution, eight fa 
fa X7, fa fa Xio> and Xn) of the 11 torsional angles were accurately 
predicted (72.7%) using the rational molecular fragmentation model. 
Although carvedilol possesses an exorbitant amount of conformational 
possibilities, by utilizing a fragmentation approach based on the basic 
thermodynamics precept that only low energy states are significantly 
occupied, the highly populated states of carvedilol have been resolved. 
The rational molecular fragmentation method applied to carvedilol relies 
not on profligate computing force, but rather on the study of rationally-
constructed fragments to generate PEHS points with some amount of 
energy minimization. This approach simplifies PEHS sampling because it 
is focused on hypothesized highly populated states. 
Fragment A 
s t ruc tura l 
pa rame te r s 
Fragment B 
structural 
pa ramete r s 
Fragment C 
J M D C A I M D C A | M D C A 
structural 
parameters 
low e n e r g y f r agmen t states selected 
(or a n o t h e r s t ructura l parameter) 
ihypotheses and predic t ions fo rmed 
structural parameters 
include: conformations, 
stereochemistry, acidity 
and basicity, etc. 
theoretical calcula t ions 
R e s o l v e d Low 
Energy States 
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